Cysteine is a sulfur-containing amino acid that is the rate-limiting substrate for the synthesis of glutathione (GSH) — the most abundant intracellular antioxidant in human cells and the primary defence against reactive oxygen species, electrophilic toxins, and the inflammatory mediators that accumulate in chronic disease. Glutathione is a tripeptide consisting of glutamate, cysteine, and glycine, and it is synthesised in two ATP-dependent steps by the enzymes gamma-glutamylcysteine synthetase (the rate-limiting step, which requires glutamate and cysteine) and glutathione synthetase (which adds glycine). The cysteine substrate is the critical variable — when cysteine availability is low, glutathione synthesis is impaired, and cells become susceptible to oxidative damage, toxin-induced cell death, and the chronic inflammation that drives most age-related diseases. This cysteine-dependent vulnerability of the glutathione system is one of the most important and least appreciated factors in cellular ageing and in the pathogenesis of the chronic diseases that are associated with oxidative stress, including neurodegenerative disease, cardiovascular disease, type 2 diabetes, and cancer.
Glutathione and the Antioxidant Defense System
Glutathione is the primary intracellular antioxidant in human cells — it directly neutralises hydrogen peroxide (H2O2) and lipid hydroperoxides (LOOH) through the glutathione peroxidase reaction, it participates in the detoxification of electrophilic compounds through the glutathione S-transferase conjugation pathway, and it maintains the reduced state of other antioxidants (including vitamin C and vitamin E) through the glutathione reductase system. The GSH-GSSG redox couple is the most important redox buffer in the cell — it maintains the cellular redox environment in a reduced state that is essential for the function of the redox-sensitive signalling pathways that regulate cell growth, differentiation, and survival. When glutathione is depleted by oxidative stress, toxin exposure, or inadequate cysteine intake, the cellular redox environment shifts toward oxidation, the NF-kappaB inflammatory pathway is activated, the Nrf2-ARE transcriptional response is inhibited, and the cell enters a state of progressive dysfunction that characterises the cellular ageing process.
The clinical consequences of glutathione depletion are broad and devastating. In the liver, glutathione depletion impairs the Phase II detoxification system, leading to the accumulation of toxic metabolites and to the hepatocellular damage that characterises toxic hepatitis and drug-induced liver injury. In the brain, glutathione depletion contributes to the neuronal death that characterises neurodegenerative diseases including Parkinson disease, Alzheimer disease, and Huntington disease. In the cardiovascular system, glutathione depletion contributes to the endothelial dysfunction, the LDL oxidation, and the vascular smooth muscle proliferation that characterise atherosclerosis. In the pancreatic beta cells, glutathione depletion contributes to the oxidative damage that impairs insulin secretion and that leads to the beta cell failure that characterises type 2 diabetes.
N-Acetylcysteine (NAC) as a Glutathione Precursor
N-acetylcysteine (NAC) is the supplemental form of cysteine that is most widely used for glutathione support. It is rapidly deacetylated to cysteine in the liver, providing a bioavailable source of cysteine for glutathione synthesis. NAC has been used clinically for over 50 years as a mucolytic agent and as an antidote to acetaminophen (paracetamol) overdose — it restores hepatic glutathione stores that are depleted by the toxic metabolite NAPQI. More recently, NAC has been studied for its effects on a broad range of conditions characterised by glutathione depletion and oxidative stress — including COPD (where a meta-analysis of 12 RCTs found that NAC at 600mg twice daily significantly reduced exacerbation rates), contrast-induced nephropathy, psychiatric disorders (as an adjunctive therapy in schizophrenia and bipolar disorder), and infertility.
Cysteine and the Transsulfuration Pathway
The transsulfuration pathway is the pathway by which cysteine is synthesised from methionine in the liver — it converts the sulfur from methionine to cysteine, allowing the body to synthesise cysteine and glutathione from dietary protein even when cysteine intake is low. The first step is catalysed by cystathionine beta-synthase (CBS), which converts homocysteine to cystathionine, and the second step is catalysed by cystathionine gamma-lyase (CGL), which converts cystathionine to cysteine. This pathway is the primary mechanism by which the body regulates its cysteine and glutathione status, and it is impaired in people with the genetic polymorphism CBS C699T (which is associated with elevated homocysteine and reduced transsulfuration activity). People with this polymorphism are at increased risk of cardiovascular disease, neural tube defects, and possibly of cognitive decline associated with elevated homocysteine — and may benefit from cysteine or NAC supplementation to compensate for the reduced transsulfuration activity.
Practical Application
For glutathione support, the evidence-based dose is 500-1,000mg of NAC daily, divided into 2 doses and taken on an empty stomach for optimal absorption. NAC is generally well-tolerated with no significant adverse effects at therapeutic doses, though very high doses can produce GI upset, nausea, and headache. An alternative to NAC is S-adenosylmethionine (SAM), which increases cysteine availability through the transsulfuration pathway, or reduced glutathione (GSH), which bypasses the need for cysteine synthesis but has poor oral bioavailability. For comprehensive antioxidant support, NAC pairs well with selenium (for the GPx enzymes), with alpha-lipoic acid (for the regeneration of other antioxidants), with vitamin C (for the regeneration of glutathione), and with the omega-3 fatty acids.
Leave a Reply